SCHEMBL7201020

SCHEMBL7201020

CC(=O)NCCC1COc2ccccc2O1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.74
HTT P42858 1/20 0.61
CA2 P00918 1/20 0.59
ALDH1A1 P00352 4/20 0.57
POLB P06746 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
HPGD P15428 4/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
AIMP2 Q13155 1/20 0.55
ALOX5 P09917 1/20 0.53
MAPT P10636 1/20 0.53
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204558 0.92 MTNR1A (0.71) MTNR1AHTTCA2ALDH1A1POLB
SCHEMBL7202212 0.85 MTNR1A (1.00) MTNR1AALDH1A1POLBSMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL11028253 0.84 MTNR1A (0.97) MTNR1AALDH1A1POLBSMN1; SMN2HPGD
SCHEMBL5341627 0.84 MTNR1A (0.72) MTNR1AHTTCA2ALDH1A1POLB
SCHEMBL7200942 0.81 MTNR1A (1.00) MTNR1AALDH1A1POLBALOX5MAPT
SCHEMBL9413231 0.80 CA2 (0.62) MTNR1AHTTCA2ALDH1A1POLB
SCHEMBL9692532 0.78 HTT (0.58) MTNR1AHTTCA2ALDH1A1POLB
SCHEMBL7198394 0.77 POLB (0.67) MTNR1AHTTALDH1A1POLBSMN1; SMN2
SCHEMBL9413211 0.77 CA2 (0.58) MTNR1AHTTCA2ALDH1A1POLB
SCHEMBL9413175 0.77 POLB (0.74) MTNR1AHTTCA2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 MTNR1A 1/4885HTT 1392/4885CA2 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.